{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:01:32Z","timestamp":1783947692434,"version":"3.55.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.cytogfr.2021.09.001","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:03:56Z","timestamp":1632182636000},"page":"70-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["The role and transformative potential of IL-19 in atherosclerosis"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1256-3201","authenticated-orcid":false,"given":"Wujun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyao","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongming","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cytogfr.2021.09.001_bib1","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cca.2020.04.037","article-title":"Butyrate-producing bacteria and the gut-heart axis in atherosclerosis","volume":"507","author":"Chen","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cytogfr.2021.09.001_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cca.2021.02.003","article-title":"Extracellular vesicle YRNA in atherosclerosis","volume":"517","author":"Chen","year":"2021","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cytogfr.2021.09.001_bib3","doi-asserted-by":"crossref","DOI":"10.2147\/JIR.S330147","article-title":"New horizons for the roles and association of APE1\/Ref-1 and ABCA1in atherosclerosis","author":"Chen","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.cytogfr.2021.09.001_bib4","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3389\/fimmu.2018.00700","article-title":"IL-19 and other IL-20 family member cytokines in vascular inflammatory diseases","volume":"9","author":"Autieri","year":"2018","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.cytogfr.2021.09.001_bib5","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1161\/ATVBAHA.113.301521","article-title":"Attenuation of experimental atherosclerosis by interleukin-19","volume":"33","author":"Ellison","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.cytogfr.2021.09.001_bib6","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.athoracsur.2011.04.061","article-title":"Induced interleukin-19 contributes to cell-mediated immunosuppression in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass","volume":"92","author":"Yeh","year":"2011","journal-title":"Ann. Thorac. Surg."},{"issue":"2","key":"10.1016\/j.cytogfr.2021.09.001_bib7","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.arcmed.2020.01.007","article-title":"IL-19 as a biomarker for the severity of acute myocardial infarction","volume":"51","author":"Qi","year":"2020","journal-title":"Arch. Med. Res."},{"issue":"1","key":"10.1016\/j.cytogfr.2021.09.001_bib8","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1038\/s41598-019-41609-z","article-title":"Assessment and clinical relevance of serum IL-19 levels in psoriasis and atopic dermatitis using a sensitive and specific novel immunoassay","volume":"9","author":"Konrad","year":"2019","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.cytogfr.2021.09.001_bib9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.atherosclerosis.2012.11.025","article-title":"MicroRNA-33 in atherosclerosis etiology and pathophysiology","volume":"227","author":"Chen","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cytogfr.2021.09.001_bib10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cca.2020.02.025","article-title":"Endogenous ApoA-I expression in macrophages: a potential target for protection against atherosclerosis","volume":"505","author":"Chen","year":"2020","journal-title":"Clin. Chim Acta"},{"key":"10.1016\/j.cytogfr.2021.09.001_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cca.2021.02.025","article-title":"The ABCA1-efferocytosis axis: a new strategy to protect against atherosclerosis","volume":"518","author":"Chen","year":"2021","journal-title":"Clin. Chim Acta"},{"issue":"1","key":"10.1016\/j.cytogfr.2021.09.001_bib12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s10020-020-00213-y","article-title":"The crosstalk of ABCA1 and ANXA1: a potential mechanism for protection against atherosclerosis","volume":"26","author":"Shen","year":"2020","journal-title":"Mol. Med."},{"key":"10.1016\/j.cytogfr.2021.09.001_bib13","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cca.2021.01.019","article-title":"Recent advances in the regulation of ABCA1 and ABCG1 by lncRNAs","volume":"516","author":"Zhang","year":"2021","journal-title":"Clin. Chim Acta"},{"issue":"2","key":"10.1016\/j.cytogfr.2021.09.001_bib14","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.atherosclerosis.2012.01.020","article-title":"The magic and mystery of microRNA-27 in atherosclerosis","volume":"222","author":"Chen","year":"2012","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.cytogfr.2021.09.001_bib15","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.ajpath.2015.12.023","article-title":"Progression of atherosclerotic plaque, polarizes, and increases cholesterol uptake and efflux in macrophages","volume":"186","author":"Gabunia","year":"2016","journal-title":"Am. J. Pathol."},{"issue":"11","key":"10.1016\/j.cytogfr.2021.09.001_bib16","doi-asserted-by":"crossref","first-page":"C931","DOI":"10.1152\/ajpcell.00006.2016","article-title":"Interleukin-19 induces angiogenesis in the absence of hypoxia by direct and indirect immune mechanisms","volume":"310","author":"Kako","year":"2016","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.cytogfr.2021.09.001_bib17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.yjmcc.2017.02.005","article-title":"Induction of MiR133a expression by IL-19 targets LDLRAP1 and reduces oxLDL uptake in VSMC","volume":"105","author":"Gabunia","year":"2017","journal-title":"J. Mol. Cell Cardiol."},{"key":"10.1016\/j.cytogfr.2021.09.001_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100062","article-title":"Lipoprotein metabolism in familial hypercholesterolemia","volume":"62","author":"Chemello","year":"2021","journal-title":"J. Lipid Res."},{"issue":"5","key":"10.1016\/j.cytogfr.2021.09.001_bib19","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/eji.200425317","article-title":"Human IL-19 regulates immunity through auto-induction of IL-19 and production of IL-10","volume":"35","author":"Jordan","year":"2005","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.cytogfr.2021.09.001_bib20","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.intimp.2004.01.005","article-title":"Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses","volume":"4","author":"Gallagher","year":"2004","journal-title":"Int. Immunopharmacol."},{"issue":"6","key":"10.1016\/j.cytogfr.2021.09.001_bib21","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1161\/ATVBAHA.118.310929","article-title":"Genetic deletion of IL-19 (Interleukin-19) exacerbates atherogenesis in Il19(-\/-)xLdlr(-\/-) double knockout mice by dysregulation of mRNA stability protein HuR (Human Antigen R)","volume":"38","author":"Ray","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"9","key":"10.1016\/j.cytogfr.2021.09.001_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/antiox9090829","article-title":"Targeting heme oxygenase-1 in the arterial response to injury and disease","volume":"9","author":"Durante","year":"2020","journal-title":"Antioxidants"},{"issue":"4","key":"10.1016\/j.cytogfr.2021.09.001_bib23","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1074\/jbc.M111.312470","article-title":"Interleukin-19 (IL-19) induces heme oxygenase-1 (HO-1) expression and decreases reactive oxygen species in human vascular smooth muscle cells","volume":"287","author":"Gabunia","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.cytogfr.2021.09.001_bib24","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/CIRCRESAHA.115.306361","article-title":"Vascular smooth muscle cells in atherosclerosis","volume":"118","author":"Bennett","year":"2016","journal-title":"Circ. Res."},{"issue":"4","key":"10.1016\/j.cytogfr.2021.09.001_bib25","doi-asserted-by":"crossref","first-page":"C896","DOI":"10.1152\/ajpcell.00439.2010","article-title":"Anti-inflammatory cytokine interleukin-19 inhibits smooth muscle cell migration and activation of cytoskeletal regulators of VSMC motility","volume":"300","author":"Gabunia","year":"2011","journal-title":"Am. J. Physiol. Cell. Physiol."},{"issue":"7","key":"10.1016\/j.cytogfr.2021.09.001_bib26","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.ajpath.2014.04.001","article-title":"IL-19 reduces ligation-mediated neointimal hyperplasia by reducing vascular smooth muscle cell activation","volume":"184","author":"Ellison","year":"2014","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.cytogfr.2021.09.001_bib27","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2353\/ajpath.2008.080163","article-title":"Expression and suppressive effects of interleukin-19 on vascular smooth muscle cell pathophysiology and development of intimal hyperplasia","volume":"173","author":"Tian","year":"2008","journal-title":"Am. J. Pathol."},{"issue":"11","key":"10.1016\/j.cytogfr.2021.09.001_bib28","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.repc.2020.05.010","article-title":"Novel biomarkers in the prognosis of patients with atherosclerotic coronary artery disease","volume":"39","author":"Freitas","year":"2020","journal-title":"Rev. Port. Cardiol."},{"issue":"3","key":"10.1016\/j.cytogfr.2021.09.001_bib29","doi-asserted-by":"crossref","first-page":"C255","DOI":"10.1152\/ajpcell.00069.2013","article-title":"Interleukin-19 decreases leukocyte-endothelial cell interactions by reduction in endothelial cell adhesion molecule mRNA stability","volume":"305","author":"England","year":"2013","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"10","key":"10.1016\/j.cytogfr.2021.09.001_bib30","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1161\/ATVBAHA.119.313034","article-title":"Regulation of stress granule formation by inflammation, vascular injury, and atherosclerosis","volume":"39","author":"Herman","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.cytogfr.2021.09.001_bib31","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.yjmcc.2010.04.016","article-title":"Il-19 reduces VSMC activation by regulation of mRNA regulatory factor HuR and reduction of mRNA stability","volume":"49","author":"Cuneo","year":"2010","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"5","key":"10.1016\/j.cytogfr.2021.09.001_bib32","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.celrep.2018.07.002","article-title":"FXR1 Is an IL-19-responsive RNA-binding protein that destabilizes pro-inflammatory transcripts in vascular smooth muscle cells","volume":"24","author":"Herman","year":"2018","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/j.cytogfr.2021.09.001_bib33","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11883-020-00883-3","article-title":"Targeting inflammation to reduce residual cardiovascular risk","volume":"22","author":"Ajala","year":"2020","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.cytogfr.2021.09.001_bib34","article-title":"Anti-inflammatory therapy for coronary atherosclerotic heart disease: unanswered questions behind existing successes","volume":"7","author":"Ma","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"issue":"16","key":"10.1016\/j.cytogfr.2021.09.001_bib35","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jacc.2016.07.768","article-title":"Arterial effects of canakinumab in patients with atherosclerosis and Type 2 diabetes or glucose intolerance","volume":"68","author":"Choudhury","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cytogfr.2021.09.001_bib36","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1475-2840-13-94","article-title":"Safety and tolerability of canakinumab, an IL-1\u03b2 inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies","volume":"13","author":"Howard","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"issue":"9","key":"10.1016\/j.cytogfr.2021.09.001_bib37","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","article-title":"Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease","volume":"126","author":"Abbate","year":"2020","journal-title":"Circ. Res."},{"issue":"3","key":"10.1016\/j.cytogfr.2021.09.001_bib38","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.amjmed.2018.10.013","article-title":"Canakinumab: promises and future in cardiometabolic diseases and malignancy","volume":"132","author":"Dhorepatil","year":"2019","journal-title":"Am. J. Med."},{"issue":"9","key":"10.1016\/j.cytogfr.2021.09.001_bib39","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/s41591-018-0124-5","article-title":"Interleukin-1beta has atheroprotective effects in advanced atherosclerotic lesions of mice","volume":"24","author":"Gomez","year":"2018","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.cytogfr.2021.09.001_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182115","article-title":"Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib","volume":"12","author":"Yeo","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.cytogfr.2021.09.001_bib41","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1001\/jamacardio.2019.0179","article-title":"Association of initial and serial C-reactive protein levels with adverse cardiovascular events and death after acute coronary syndrome: a secondary analysis of the VISTA-16 Trial","volume":"4","author":"Mani","year":"2019","journal-title":"JAMA Cardiol."},{"issue":"3","key":"10.1016\/j.cytogfr.2021.09.001_bib42","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/jama.2013.282836","article-title":"V.-. Investigators, Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial","volume":"311","author":"Nicholls","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.cytogfr.2021.09.001_bib43","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.25011\/cim.v36i1.19403","article-title":"Amelioration of atherosclerosis in apolipoprotein E-deficient mice by inhibition of lipoprotein-associated phospholipase A2","volume":"36","author":"Zhang","year":"2013","journal-title":"Clin. Investig. Med."},{"issue":"8","key":"10.1016\/j.cytogfr.2021.09.001_bib44","doi-asserted-by":"crossref","first-page":"23425","DOI":"10.1371\/journal.pone.0023425","article-title":"Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice","volume":"6","author":"Wang","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.cytogfr.2021.09.001_bib45","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/FJC.0b013e318195bfbc","article-title":"Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-\/- mice","volume":"53","author":"Fraser","year":"2009","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"4","key":"10.1016\/j.cytogfr.2021.09.001_bib46","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1194\/jlr.M800361-JLR200","article-title":"The synergistic inhibition of atherogenesis in apoE-\/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002)","volume":"50","author":"Shaposhnik","year":"2009","journal-title":"J. Lipid Res."},{"issue":"12","key":"10.1016\/j.cytogfr.2021.09.001_bib47","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1161\/ATVBAHA.113.301410","article-title":"Expression of type IIA secretory phospholipase A2 inhibits cholesteryl ester transfer protein activity in transgenic mice","volume":"33","author":"Hurt-Camejo","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.cytogfr.2021.09.001_bib48","unstructured":"Fulcrum Therapeutics Receives Orphan Drug Designation for Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) and Announces Expanded Patent Portfolio [press release], Fulcrum Therapeutics, Inc."},{"issue":"5","key":"10.1016\/j.cytogfr.2021.09.001_bib49","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ahj.2015.02.012","article-title":"Rationale and design of the losmapimod to inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial","volume":"169","author":"O\u2019Donoghue","year":"2015","journal-title":"Am. Heart J."},{"issue":"4","key":"10.1016\/j.cytogfr.2021.09.001_bib50","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jcct.2019.12.033","article-title":"Effect of 5-lipoxygenase inhibitor, VIA-2291 (Atreleuton), on epicardial fat volume in patients with recent acute coronary syndrome","volume":"14","author":"Almeida","year":"2020","journal-title":"J. Cardiovasc. Comput. Tomogr."},{"issue":"1","key":"10.1016\/j.cytogfr.2021.09.001_bib51","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2015.02.027","article-title":"A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome","volume":"240","author":"Gaztanaga","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cytogfr.2021.09.001_bib52","unstructured":"VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease, VIA Pharmaceuticals, Inc."},{"issue":"17","key":"10.1016\/j.cytogfr.2021.09.001_bib53","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1016\/j.bmc.2019.06.040","article-title":"5-Lipoxygenase as a drug target: a review on trends in inhibitors structural design, SAR and mechanism based approach","volume":"27","author":"Sinha","year":"2019","journal-title":"Bioorg. Med. Chem."},{"issue":"3","key":"10.1016\/j.cytogfr.2021.09.001_bib54","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.rmed.2010.09.021","article-title":"MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease","volume":"105","author":"Bernstein","year":"2011","journal-title":"Respir. Med."},{"issue":"1","key":"10.1016\/j.cytogfr.2021.09.001_bib55","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1124\/jpet.110.166967","article-title":"Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain","volume":"334","author":"Masferrer","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"18","key":"10.1016\/j.cytogfr.2021.09.001_bib56","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1001\/jama.293.18.2245","article-title":"Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial","volume":"293","author":"Hakonarson","year":"2005","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.cytogfr.2021.09.001_bib57","first-page":"583","article-title":"BAY x 1005 attenuates atherosclerosis in apoE\/LDLR - double knockout mice","volume":"58","author":"Jawien","year":"2007","journal-title":"J. Physiol. Pharmacol."},{"issue":"3","key":"10.1016\/j.cytogfr.2021.09.001_bib58","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"issue":"8","key":"10.1016\/j.cytogfr.2021.09.001_bib59","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"C. Investigators, low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.cytogfr.2021.09.001_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201601286","article-title":"Methotraxate-loaded hybrid nanoconstructs target vascular lesions and inhibit atherosclerosis progression in ApoE(-\/-) Mice","volume":"6","author":"Stigliano","year":"2017","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.cytogfr.2021.09.001_bib61","doi-asserted-by":"crossref","unstructured":"P.M. Ridker, M. Devalaraja, F.M.M. Baeres, M.D.M. Engelmann, G.K. Hovingh, M. Ivkovic, L. Lo, D. Kling, P. Pergola, D. Raj, P. Libby, M. Davidson, R. Investigators, IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial, Lancet (2021).","DOI":"10.1016\/S0140-6736(21)00520-1"},{"issue":"1","key":"10.1016\/j.cytogfr.2021.09.001_bib62","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41569-020-0431-7","article-title":"Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6","volume":"18","author":"Tyrrell","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"issue":"2","key":"10.1016\/j.cytogfr.2021.09.001_bib63","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2019-001108","article-title":"Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI)","volume":"6","author":"Anstensrud","year":"2019","journal-title":"Open Heart"},{"issue":"30","key":"10.1016\/j.cytogfr.2021.09.001_bib64","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1093\/eurheartj\/ehw171","article-title":"Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial","volume":"37","author":"Kleveland","year":"2016","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.cytogfr.2021.09.001_bib65","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1021\/acs.jmedchem.0c01307","article-title":"Strategies for targeting the NLRP3 inflammasome in the clinical and preclinical space","volume":"64","author":"Schwaid","year":"2021","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.cytogfr.2021.09.001_bib66","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/eurheartj\/ehu272","article-title":"The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study","volume":"36","author":"Morton","year":"2015","journal-title":"Eur. Heart J."},{"issue":"10","key":"10.1016\/j.cytogfr.2021.09.001_bib67","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.amjcard.2013.01.287","article-title":"Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]","volume":"111","author":"Abbate","year":"2013","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"10.1016\/j.cytogfr.2021.09.001_bib68","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.amjcard.2014.11.003","article-title":"Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies)","volume":"115","author":"Abbate","year":"2015","journal-title":"Am. J. Cardiol."},{"issue":"5","key":"10.1016\/j.cytogfr.2021.09.001_bib69","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014941","article-title":"Interleukin-1 blockade inhibits the acute inflammatory response in patients with ST-segment-elevation myocardial infarction","volume":"9","author":"Abbate","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"8","key":"10.1016\/j.cytogfr.2021.09.001_bib70","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/clc.22988","article-title":"Rationale and design of the virginia commonwealth university-anakinra remodeling Trial-3 (VCU-ART3): a randomized, placebo-controlled, double-blinded, multicenter study","volume":"41","author":"Van Tassell","year":"2018","journal-title":"Clin. Cardiol."},{"issue":"3","key":"10.1016\/j.cytogfr.2021.09.001_bib71","doi-asserted-by":"crossref","first-page":"33438","DOI":"10.1371\/journal.pone.0033438","article-title":"Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure","volume":"7","author":"Van Tassell","year":"2012","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.cytogfr.2021.09.001_bib72","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/cti2.1206","article-title":"Inhibition of interleukin-1\u03b2 signalling promotes atherosclerotic lesion remodelling in mice with inflammatory arthritis","volume":"9","author":"Dragoljevic","year":"2020","journal-title":"Clin. Transl. Immunol."},{"issue":"2","key":"10.1016\/j.cytogfr.2021.09.001_bib73","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.15896","article-title":"Colchicine: an ancient drug with novel applications","volume":"178","author":"Dasgeb","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.cytogfr.2021.09.001_bib74","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"I. LoDoCo2 Trial, Colchicine in patients with chronic coronary disease","author":"Nidorf","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.cytogfr.2021.09.001_bib75","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2021.09.001_bib76","doi-asserted-by":"crossref","unstructured":"A. Aimo, D.A. Pascual-Figal, A. Barison, G. Cediel, A.H. Vicente, L.F. Saccaro, M. Emdin, A. Bayes-Genis, Colchicine for the treatment of coronary artery disease, Trends Cardiovasc. Med. (2020).","DOI":"10.1016\/j.tcm.2020.10.007"},{"issue":"1","key":"10.1016\/j.cytogfr.2021.09.001_bib77","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.clinthera.2018.11.016","article-title":"Why colchicine should be considered for secondary prevention of atherosclerosis: an overview","volume":"41","author":"Nidorf","year":"2019","journal-title":"Clin. Ther."},{"issue":"1","key":"10.1016\/j.cytogfr.2021.09.001_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22010173","article-title":"PI3K\/AKT\/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects","volume":"22","author":"Miricescu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"18","key":"10.1016\/j.cytogfr.2021.09.001_bib79","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa0910496","article-title":", Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease","volume":"362","author":"Stone","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.cytogfr.2021.09.001_bib80","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.jcin.2020.04.021","article-title":"Titanium-nitride-oxide-coated versus everolimus-eluting stents in acute coronary syndrome: the randomized TIDES-ACS trial","volume":"13","author":"Tonino","year":"2020","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.cytogfr.2021.09.001_bib81","unstructured":"L. Chhabra, M.A. Zain, W.J. Siddiqui, Coronary Stents, StatPearls, Treasure Island (FL), 2021."},{"issue":"1","key":"10.1016\/j.cytogfr.2021.09.001_bib82","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2007.09.019","article-title":"Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-\/- mice despite severe hypercholesterolemia","volume":"198","author":"Mueller","year":"2008","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.cytogfr.2021.09.001_bib83","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.atherosclerosis.2012.03.003","article-title":"Effect of everolimus on pre-existing atherosclerosis in LDL-receptor deficient mice","volume":"222","author":"Beutner","year":"2012","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.cytogfr.2021.09.001_bib84","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.hjc.2018.01.013","article-title":"Everolimus as cancer therapy: cardiotoxic or an unexpected antiatherogenic agent? A narrative review","volume":"59","author":"Karvelas","year":"2018","journal-title":"Hellenic J. Cardiol."},{"key":"10.1016\/j.cytogfr.2021.09.001_bib85","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.vph.2018.12.004","article-title":"Everolimus depletes plaque macrophages, abolishes intraplaque neovascularization and improves survival in mice with advanced atherosclerosis","volume":"113","author":"Kurdi","year":"2019","journal-title":"Vascul. Pharmacol."},{"issue":"3","key":"10.1016\/j.cytogfr.2021.09.001_bib86","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.semarthrit.2019.11.009","article-title":"Beyond urate lowering: analgesic and anti-inflammatory properties of allopurinol","volume":"50","author":"Schlesinger","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.cytogfr.2021.09.001_bib87","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013774","article-title":", Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study","volume":"6","author":"Mackenzie","year":"2016","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.cytogfr.2021.09.001_bib88","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1161\/ATVBAHA.111.234559","article-title":"Xanthine oxidoreductase is involved in macrophage foam cell formation and atherosclerosis development","volume":"32","author":"Kushiyama","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"12","key":"10.1016\/j.cytogfr.2021.09.001_bib89","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1248\/bpb.b14-00201","article-title":"Is hyperuricemia a risk factor for arteriosclerosis? Uric acid and arteriosclerosis in apolipoprotein e-deficient mice","volume":"37","author":"Wakuda","year":"2014","journal-title":"Biol. Pharm. Bull."},{"issue":"3","key":"10.1016\/j.cytogfr.2021.09.001_bib90","first-page":"633","article-title":"The effect of montelukast on atherogenesis in apoE\/LDLR-double knockout mice","volume":"59","author":"Jawien","year":"2008","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/j.cytogfr.2021.09.001_bib91","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.phrs.2018.06.014","article-title":"Cysteinyl-leukotriene pathway as a new therapeutic target for the treatment of atherosclerosis related to obstructive sleep apnea syndrome","volume":"134","author":"Gautier-Veyret","year":"2018","journal-title":"Pharmacol. Res."},{"issue":"5","key":"10.1016\/j.cytogfr.2021.09.001_bib92","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/bph.14549","article-title":"Exogenous IL-19 attenuates acute ischaemic injury and improves survival in male mice with myocardial infarction","volume":"176","author":"An","year":"2019","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.cytogfr.2021.09.001_bib93","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.2353\/ajpath.2007.060857","article-title":"Interleukin-4 does not influence development of hypercholesterolemia or angiotensin II-induced atherosclerotic lesions in mice","volume":"171","author":"King","year":"2007","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.cytogfr.2021.09.001_bib94","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1084\/jem.20071868","article-title":"IL-33 reduces the development of atherosclerosis","volume":"205","author":"Miller","year":"2008","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.cytogfr.2021.09.001_bib95","doi-asserted-by":"crossref","first-page":"13459","DOI":"10.1111\/eci.13459","article-title":"PCSK9 and atherosclerosis: looking beyond LDL regulation","volume":"51","author":"Ragusa","year":"2021","journal-title":"Eur. J. Clin. Investig."},{"issue":"10","key":"10.1016\/j.cytogfr.2021.09.001_bib96","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1194\/jlr.M051326","article-title":"Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin","volume":"55","author":"Kuhnast","year":"2014","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.cytogfr.2021.09.001_bib97","first-page":"2266","article-title":"Atorvastatin inhibits endoplasmic reticulum stress through AMPK signaling pathway in atherosclerosis in mice","volume":"19","author":"Xiong","year":"2020","journal-title":"Exp. Ther. Med."},{"issue":"13","key":"10.1016\/j.cytogfr.2021.09.001_bib98","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1111\/bph.14193","article-title":"Treatment with IL-19 improves locomotor functional recovery after contusion trauma to the spinal cord","volume":"175","author":"Guo","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.cytogfr.2021.09.001_bib99","first-page":"172","article-title":"Interleukin-19 alleviates brain injury by anti-inflammatory effects in a mice model of focal cerebral ischemia","volume":"2016","author":"Xie","year":"1650","journal-title":"Brain Res."},{"key":"10.1016\/j.cytogfr.2021.09.001_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.615898","article-title":"Interleukin-19 abrogates experimental autoimmune encephalomyelitis by attenuating antigen-presenting cell activation","volume":"12","author":"Horiuchi","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2021.09.001_bib101","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12950-018-0195-6","article-title":"The roles of IL-19 and IL-20 in the inflammation of degenerative lumbar spondylolisthesis","volume":"15","author":"Huang","year":"2018","journal-title":"J. Inflamm."},{"key":"10.1016\/j.cytogfr.2021.09.001_bib102","doi-asserted-by":"crossref","DOI":"10.1186\/s10020-021-00358-4","article-title":"New horizons in the roles and associations of COX-2 and novel natural inhibitors in cardiovascular diseases","author":"Chen","year":"2021","journal-title":"Mol. Med."},{"issue":"5","key":"10.1016\/j.cytogfr.2021.09.001_bib103","doi-asserted-by":"crossref","first-page":"382","DOI":"10.2174\/1568009618666181031145953","article-title":", The RNA binding protein HuR: a promising drug target for anticancer therapy","volume":"19","author":"Wu","year":"2019","journal-title":"Curr. Cancer Drug Targets"},{"issue":"10","key":"10.1016\/j.cytogfr.2021.09.001_bib104","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/aps.2011.127","article-title":"The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice","volume":"32","author":"Hu","year":"2011","journal-title":"Acta Pharmacol. Sin."}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135961012100068X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135961012100068X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T10:58:27Z","timestamp":1761217107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135961012100068X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":104,"alternative-id":["S135961012100068X"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2021.09.001","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role and transformative potential of IL-19 in atherosclerosis","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2021.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}